Regenerx Biopharm In Stock Cash And Equivalents
| RGRXDelisted Stock | USD 0.03 0.01 25.00% |
Regenerx Biopharm In fundamentals help investors to digest information that contributes to Regenerx Biopharm's financial success or failures. It also enables traders to predict the movement of Regenerx OTC Stock. The fundamental analysis module provides a way to measure Regenerx Biopharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regenerx Biopharm otc stock.
Regenerx |
Regenerx Biopharm In OTC Stock Cash And Equivalents Analysis
Regenerx Biopharm's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Regenerx Biopharm Cash And Equivalents | 478.41 K |
Most of Regenerx Biopharm's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regenerx Biopharm In is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Regenerx Biopharm In has 478.41 K in Cash And Equivalents. This is 99.94% lower than that of the Biotechnology sector and 99.89% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.98% higher than that of the company.
Regenerx Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regenerx Biopharm's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Regenerx Biopharm could also be used in its relative valuation, which is a method of valuing Regenerx Biopharm by comparing valuation metrics of similar companies.Regenerx Biopharm is currently under evaluation in cash and equivalents category among its peers.
Regenerx Fundamentals
| Return On Asset | -0.84 | ||||
| Operating Margin | (19.03) % | ||||
| Current Valuation | 22.91 M | ||||
| Shares Outstanding | 143.55 M | ||||
| Shares Owned By Insiders | 45.99 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 19.19 K | ||||
| Price To Earning | 17.73 X | ||||
| Price To Sales | 261.81 X | ||||
| Revenue | 76.76 K | ||||
| Gross Profit | 70.12 K | ||||
| EBITDA | (1.27 M) | ||||
| Net Income | (1.6 M) | ||||
| Cash And Equivalents | 478.41 K | ||||
| Total Debt | 1.14 M | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (990.3 K) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 1.5 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 20.1 M | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (105.27 M) | ||||
| Working Capital | 806 K | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 382 K | ||||
| Net Asset | 1.28 M |
About Regenerx Biopharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regenerx Biopharm In's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regenerx Biopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regenerx Biopharm In based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Regenerx OTC Stock
If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |